Practice Guidelines

ACP Updates Guideline on Oral Pharmacologic Treatments for Type 2 Diabetes Mellitus



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2013 Jan 15;87(2):140-144.

Guideline source: American College of Physicians

Evidence rating system used? Yes

Literature search described? Yes

Guideline developed by participants without relevant financial ties to industry? No

Published source:Annals of Internal Medicine, February 2012

Available at: http://annals.org/article.aspx?volume=156&page=218

Endorsed by the AAFP, May 2013. http://www.aafp.org/patient-care/clinical-recommendations/all/endorsed.html

Diabetes mellitus is the seventh leading cause of death in the United States. The most common form is type 2, which affects about 25.8 million Americans. Type 2 diabetes increases with age—nearly 27 percent of U.S. adults older than 65 years have the disease. In 2007, the costs associated with diabetes reached $174 billion in the United States. Most persons diagnosed with diabetes take more than one class of medication to treat complications such as hyperglycemia and retinopathy; 58 percent take only oral medications, and 14 percent take oral medications and insulin.

The American College of Physicians (ACP) has published an updated guideline on the oral pharmacologic management of type 2 diabetes. Recommendations are based on a systematic evidence review of head-to-head comparisons of oral pharmacologic treatments for type 2 diabetes, and an evidence report sponsored by the Agency for Healthcare Research and Quality.

Recommendations

When lifestyle modifications, including diet, exercise, and weight loss, do not adequately improve hyperglycemia in patients diagnosed with type 2 diabetes, physicians should add oral pharmacologic therapy.

Initiating oral pharmacologic therapy is important for managing type 2 diabetes effectively. Because there are no data on the best time to add oral therapies to lifestyle modifications, other factors such as the patient's life expectancy and preferred method of receiving medications, the presence or absence of microvascular and macrovascular complications, and the risk of adverse events related to glucose control should be considered to avoid placing an unacceptable burden on the patient. An A1C level less than 7 percent based on individualized assessment is a reasonable goal for many, but not all, patients. The A1C goal should be set after assessing risk of comorbidity, complications from diabetes, life expectancy, and patient preferences.

Physicians should prescribe metformin (Glucophage) as the initial pharmacologic therapy to treat most patients with type 2 diabetes.

Unless contraindicated, metformin is considered the preferred choice for patients with type 2 diabetes. Evidence shows that metformin is the most effective pharmacologic agent as monotherapy and in combination with other medications. It is more effective than other pharmacologic agents in reducing glycemic, low-density lipoprotein cholesterol, and triglyceride levels, and it does not cause weight gain. Metformin has been associated with slightly lower all-cause mortality and cardiovascular mortality compared with sulfonylureas. In addition, it is associated with fewer hypoglycemic episodes, and is less expensive than other pharmacologic agents.

Metformin is contraindicated in patients with impaired kidney function, decreased tissue perfusion or hemodynamic instability, liver disease, alcohol abuse, heart failure, and any condition that may lead to lactic acidosis. It is also associated with an increased risk of adverse gastrointestinal effects.

Other diabetes medications may also cause adverse effects. Sulfonylureas and meglitinides are associated with an increased risk of hypoglycemia. Thiazolidinediones are associated with an increased risk of heart failure, but there is no conclusive evidence that they increase ischemic cardiovascular risk. Physicians and patients should discuss adverse events before selecting a medication regimen.

When lifestyle modifications and monotherapy do not adequately control hyperglycemia, physicians should add a second agent to metformin to treat patients with persistent hyperglycemia.

All dual-therapy regimens reviewed by the ACP were more effective than monotherapies in reducing A1C levels by approximately one additional percentage point. Although some evidence suggests that the combination of metformin and another agent tends to be more effective than any other monotherapy or combination therapy, there is no good evidence to support one particular combination therapy over another.

Combination therapies are associated with an increased risk of adverse effects compared with mono-therapy. Although generic sulfonylureas are the least expensive second-line therapy, evidence suggests that adverse effects are generally worse with combination therapies that include a sulfonylurea. Some patients with persistent hyperglycemia may also need insulin therapy.

A comparison of pharmacologic therapies for the treatment of diabetes is included in Table 1.

Table 1.

Key Findings and Strength of Evidence for Long-Term Outcomes of Treatments for Type 2 Diabetes Mellitus

Comparison All-cause mortality Cardiovascular mortality Cardiovascular and cerebrovascular morbidity Nephropathy and neuropathy

Monotherapy vs. monotherapy

Metformin (Glucophage) vs.

TZD

Neither favored, low

Neither favored, low

Unclear, low

Favors pioglitazone,* moderate

Sulfonylurea

Favors metformin, low

Favors metformin, low

Unclear, low

Unclear, low*; insufficient†

DPP-4 inhibitor

Unclear, low

Insufficient

Insufficient

Insufficient

Meglitinide

Unclear, low

Unclear, low

Unclear, low

Insufficient

GLP-1 agonist

Insufficient

Insufficient

Insufficient

Insufficient

TZD vs.

TZD

Insufficient

Insufficient

Unclear, low

Insufficient

Sulfonylurea

Neither favored, low

Unclear, low

Unclear, low

Unclear, low*

DPP-4 inhibitor

Insufficient

Insufficient

Insufficient

Insufficient

Meglitinide

Insufficient

Insufficient

Insufficient

Unclear, low*

GLP-1 agonist

Unclear, low

Insufficient

Unclear, low

Insufficient

Sulfonylurea vs.

DPP-4 inhibitor

Insufficient

Insufficient

Insufficient

Insufficient

Meglitinide

Unclear, low

Unclear, low

Unclear, low

Insufficient

GLP-1 agonist

Insufficient

Insufficient

Insufficient

Insufficient

DPP-4 inhibitor vs.

Meglitinide

Insufficient

Insufficient

Insufficient

Insufficient

GLP-1 agonist

Insufficient

Insufficient

Insufficient

Insufficient

Monotherapy vs. combination therapy

Metformin vs.

Metformin plus TZD

Unclear, low

Unclear, low

Unclear, low

Insufficient*; unclear, low†

Metformin plus sulfonylurea

Neither favored, low

Unclear, low

Favors metformin, low

Insufficient

Metformin plus DPP-4 inhibitor

Unclear, low

Unclear, low

Unclear, low

Insufficient*; unclear, low†

Metformin plus meglitinide

Unclear, low

Unclear, low

Unclear, low

Insufficient

Combination therapy vs. combination therapy

Metformin plus another agent vs.

Metformin plus TZD

Unclear, low

Unclear, low

Unclear, low

Conclusion unclear for nephropathy and neuropathy, low

Metformin plus sulfonylurea

Unclear, low

Unclear, low

Unclear, low

Insufficient

Metformin plus meglitinide

Unclear, low

Insufficient

Insufficient

Insufficient

Metformin plus DPP-4 inhibitor

Unclear, low

Unclear, low

Unclear, low

Insufficient

Metformin plus GLP-1 agonist

Insufficient

Unclear, low

Insufficient

Insufficient

Metformin plus basal insulin

Insufficient

Unclear, low

Unclear, low

Insufficient

Metformin plus premixed insulin

Unclear, low

Unclear, low

Insufficient

Insufficient

TZD plus another agent vs.

Metformin plus TZD

Insufficient

Insufficient

Unclear, low

Insufficient

Metformin plus sulfonylurea

Unclear, low

Insufficient

Unclear, low

Insufficient

Metformin plus meglitinide

Unclear, low

Insufficient

Insufficient

Insufficient

Metformin plus DPP-4 inhibitor

Insufficient

Insufficient

Insufficient

Insufficient

Metformin plus GLP-1 agonist

Insufficient

Insufficient

Insufficient

Insufficient

Metformin plus basal insulin

Unclear, low

Insufficient

Insufficient

Insufficient

Metformin plus premixed insulin

Unclear, low

Insufficient

Unclear, low

Insufficient


DPP = dipeptidyl-peptidase; GLP = glucagon-like peptide; TZD = thiazolidinedione.

*—Key finding for nephropathy.

†—Key finding for neuropathy.

Adapted with permission from Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156(3):W-43.

Table 1.   Key Findings and Strength of Evidence for Long-Term Outcomes of Treatments for Type 2 Diabetes Mellitus

View Table

Table 1.

Key Findings and Strength of Evidence for Long-Term Outcomes of Treatments for Type 2 Diabetes Mellitus

Comparison All-cause mortality Cardiovascular mortality Cardiovascular and cerebrovascular morbidity Nephropathy and neuropathy

Monotherapy vs. monotherapy

Metformin (Glucophage) vs.

TZD

Neither favored, low

Neither favored, low

Unclear, low

Favors pioglitazone,* moderate

Sulfonylurea

Favors metformin, low

Favors metformin, low

Unclear, low

Unclear, low*; insufficient†

DPP-4 inhibitor

Unclear, low

Insufficient

Insufficient

Insufficient

Meglitinide

Unclear, low

Unclear, low

Unclear, low

Insufficient

GLP-1 agonist

Insufficient

Insufficient

Insufficient

Insufficient

TZD vs.

TZD

Insufficient

Insufficient

Unclear, low

Insufficient

Sulfonylurea

Neither favored, low

Unclear, low

Unclear, low

Unclear, low*

DPP-4 inhibitor

Insufficient

Insufficient

Insufficient

Insufficient

Meglitinide

Insufficient

Insufficient

Insufficient

Unclear, low*

GLP-1 agonist

Unclear, low

Insufficient

Unclear, low

Insufficient

Sulfonylurea vs.

DPP-4 inhibitor

Insufficient

Insufficient

Insufficient

Insufficient

Meglitinide

Unclear, low

Unclear, low

Unclear, low

Insufficient

GLP-1 agonist

Insufficient

Insufficient

Insufficient

Insufficient

DPP-4 inhibitor vs.

Meglitinide

Insufficient

Insufficient

Insufficient

Insufficient

GLP-1 agonist

Insufficient

Insufficient

Insufficient

Insufficient

Monotherapy vs. combination therapy

Metformin vs.

Metformin plus TZD

Unclear, low

Unclear, low

Unclear, low

Insufficient*; unclear, low†

Metformin plus sulfonylurea

Neither favored, low

Unclear, low

Favors metformin, low

Insufficient

Metformin plus DPP-4 inhibitor

Unclear, low

Unclear, low

Unclear, low

Insufficient*; unclear, low†

Metformin plus meglitinide

Unclear, low

Unclear, low

Unclear, low

Insufficient

Combination therapy vs. combination therapy

Metformin plus another agent vs.

Metformin plus TZD

Unclear, low

Unclear, low

Unclear, low

Conclusion unclear for nephropathy and neuropathy, low

Metformin plus sulfonylurea

Unclear, low

Unclear, low

Unclear, low

Insufficient

Metformin plus meglitinide

Unclear, low

Insufficient

Insufficient

Insufficient

Metformin plus DPP-4 inhibitor

Unclear, low

Unclear, low

Unclear, low

Insufficient

Metformin plus GLP-1 agonist

Insufficient

Unclear, low

Insufficient

Insufficient

Metformin plus basal insulin

Insufficient

Unclear, low

Unclear, low

Insufficient

Metformin plus premixed insulin

Unclear, low

Unclear, low

Insufficient

Insufficient

TZD plus another agent vs.

Metformin plus TZD

Insufficient

Insufficient

Unclear, low

Insufficient

Metformin plus sulfonylurea

Unclear, low

Insufficient

Unclear, low

Insufficient

Metformin plus meglitinide

Unclear, low

Insufficient

Insufficient

Insufficient

Metformin plus DPP-4 inhibitor

Insufficient

Insufficient

Insufficient

Insufficient

Metformin plus GLP-1 agonist

Insufficient

Insufficient

Insufficient

Insufficient

Metformin plus basal insulin

Unclear, low

Insufficient

Insufficient

Insufficient

Metformin plus premixed insulin

Unclear, low

Insufficient

Unclear, low

Insufficient


DPP = dipeptidyl-peptidase; GLP = glucagon-like peptide; TZD = thiazolidinedione.

*—Key finding for nephropathy.

†—Key finding for neuropathy.

Adapted with permission from Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156(3):W-43.

Coverage of guidelines from other organizations does not imply endorsement by AFP or the AAFP.

A collection of Practice Guidelines published inAFPis available at http://www.aafp.org/afp/practguide.


Copyright © 2013 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article